Welcome to your Weekly Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Eleos Unveils Polaris AI Model for Post-Acute Care
Eleos, the leader in AI for post-acute care, announced the launch of Polaris AI, built in collaboration with Google Cloud technology. Polaris AI is enabled by Google Cloud’s family of multimodal models and built on its secure, scalable infrastructure, combined with Eleos’ purpose-built dataset spanning millions of real-world behavioral health sessions. Eleos is delivering one of the most advanced foundational AI models designed for the unique demands of post-acute care, from rising clinician burnout to intensifying regulatory scrutiny across behavioral health, substance use disorder (SUD), home health and hospice care.
Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions
Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries.
LyfeSci Launches to Advance Outcomes-Focused Clinical Research
LyfeSci Research & Innovation, a newly established Contract Research Organization (CRO) led by physicians, is officially launching with a clear mission to transform the clinical research landscape. Rooted in a site-first approach and an unwavering focus on patient outcomes, LyfeSci combines robust clinical insight with a human-centered strategy. The organization offers a broad range of research services that extend from pre-clinical development to studies involving real-world data and evidence.
Hyro Raises $45 Million to Boost AI Agent Use in Healthcare
Hyro, a leader in responsible AI agent technology for the healthcare industry, has announced a $45 million growth funding round led by Healthier Capital, with participation from Norwest, Define Ventures, and existing investors. The funding also includes new strategic backing from Bon Secours Mercy Health, one of Hyro’s long-standing partners, and ServiceNow Ventures, the investment division of ServiceNow. This round comes less than a year after the company’s previous raise and effectively doubles its valuation, bringing total funding to $95 million. The capital infusion will help accelerate the development of AI-driven administrative, operational, and clinical agents that simplify patient access and improve digital experiences across communication channels.
LGI Healthcare and Aurora Partner for AI Revenue Cycle Management
LGI Healthcare Solutions, known for its advanced healthcare automation technologies, has formed a strategic partnership with Aurora Healthcare, a recognized leader in revenue cycle management innovation. This collaboration combines Aurora’s AI-driven Revenue Cycle Intelligence platform with LGI’s Automation Agent, an automation tool widely trusted by healthcare providers for its efficiency, reliability, and compliance.
Opyn Health Acquires Empara to Enhance Benefits Engagement
Opyn Health, a leader in price transparency, virtual care, and provider directory services, has acquired Empara, an innovative AI-powered benefits engagement and administration platform. This acquisition supports their shared goal of simplifying healthcare by integrating Empara’s advanced AI platform and user-friendly member app with Opyn’s extensive product offerings and data capabilities.
Alife Health Gets CE Mark for AI Embryo Selection Tool
Alife Health, a health tech company advancing the future of fertility care with artificial intelligence, announced that Embryo Predict, its AI-powered embryo selection tool, has received CE Mark certification under the European Medical Device Regulation (MDR). This approval marks a new era for Alife’s expansion into international markets and brings its cutting-edge technology to healthcare providers throughout Europe.
L-Nutra Launches Prolon Guided Health Program for Wellness
L-Nutra, the global leader in longevity and medical nutrition science, announced the launch of the Prolon Guided Health Program for Weight and Metabolic Wellness, the first in its new suite of Prolon Guided Health Programs. This launch marks a strategic expansion of L-Nutra’s leadership in medical nutrition – uniting patented nutrition technology with clinician-guided expertise to help individuals achieve sustainable fat-focused weight loss, protect lean muscle, and improve long-term metabolic and heart health.
MiraSol Health Hires Dr. Rahul Parimoo to Serve as Chief Medical Officer
MiraSol Health, a leading community-based nonprofit provider of compassionate palliative, end-of-life, and grief care services in Beaufort, Jasper, Colleton, and Hampton counties, is excited to announce the appointment of Dr. Rahul Parimoo as its Chief Medical Officer (CMO). Dr. Parimoo is the first CMO dedicated to a hospice and palliative program residing and working in the Lowcountry, physically seeing patients in their homes.
Rani Therapeutics Adds New Members to Board
Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced the appointment of Abraham Bassan and Vasudev Bailey, Ph.D., to its Board of Directors. In conjunction with the new appointments, Andrew Farquharson and Maulik Nanavaty have stepped down from the Board of Directors.
Avextra Backs Phase II Trial on Cannabis for Neuro Diseases
Neurodegenerative diseases are among the biggest health issues we face presently. In Germany, about 1.8 million people are living with dementia, and that number is likely to rise to 2.7 million by 2050. As people are living longer and more people are developing these conditions, it’s putting a lot of pressure on patients, their loved ones, and the healthcare system. Even though there have been some advances in research, there’s still not enough effective treatment to help reduce symptoms and improve the lives of those affected.
To share your insights, please write to us at sudipto@intentamplify.com
